ArticleJournal of the American Society of Nephrology : JASN2009
Stem cell therapies benefit Alport syndrome.
Article in Journal of the American Society of Nephrology : JASN, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Clinical practice recommendations for the treatment of Alport syndrome: a statement of the Alport Syndrome Research Collaborative.Pediatric nephrology (Berlin, Germany) · 2013Guideline
- Targeted therapeutic strategies for the kidney.Expert opinion on therapeutic targets · 2024Review
- Genetic reprogramming with stem cells regenerates glomerular epithelial podocytes in Alport syndrome.Life science alliance · 2024Article
- Progress in therapeutic targets on podocyte for Alport syndrome.Journal of translational internal medicine · 2024Article
- Cell and gene therapy for kidney disease.Nature reviews. Nephrology · 2023Review
- Spotlight on Genetic Kidney Diseases: A Call for Drug Delivery and Nanomedicine Solutions.ACS nano · 2023Review
- Genetic Disorders of the Extracellular Matrix: From Cell and Gene Therapy to Future Applications in Regenerative Medicine.Annual review of genomics and human genetics · 2022Review
- Mechanotransduction through adhesion molecules: Emerging roles in regulating the stem cell niche.Frontiers in cell and developmental biology · 2022Review
- Transplantation of umbilical cord mesenchymal stem cells into mice with focal segmental glomerulosclerosis delayed disease manifestation.Annals of translational medicine · 2019Article
- Renal, auricular, and ocular outcomes of Alport syndrome and their current management.Pediatric nephrology (Berlin, Germany) · 2018Article
- Alport syndrome: facts and opinions.F1000Research · 2017Review
- Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome.Matrix biology : journal of the International Society for Matrix Biology · 2017Review
- Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease.EBioMedicine · 2015Article
- Searching for a treatment for Alport syndrome using mouse models.World journal of nephrology · 2014Review
- Alport syndrome: its effects on the glomerular filtration barrier and implications for future treatment.The Journal of physiology · 2014Review
- Feasibility of repairing glomerular basement membrane defects in Alport syndrome.Journal of the American Society of Nephrology : JASN · 2014Article
- The emergence of the glomerular parietal epithelial cell.Nature reviews. Nephrology · 2014Review
- Origin and function of myofibroblasts in kidney fibrosis.Nature medicine · 2013Article
- An update on the pathomechanisms and future therapies of Alport syndrome.Pediatric nephrology (Berlin, Germany) · 2013Review
- Danger control programs cause tissue injury and remodeling.International journal of molecular sciences · 2013Review
Corrections and comments
- Commented on by
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with Alport syndrome progressively lose renal function as a result of defective type IV collagen in their glomerular basement membrane. In mice lacking the alpha3 chain of type IV collagen (Col4A3 knockout mice), a model for Alport syndrome, transplantation of wild-type bone marrow repairs the renal disease. It is unknown whether cell-based therapies that do not require transplantation have similar potential. Here, infusion of wild-type bone marrow-derived cells into unconditioned, nonirradiated Col4A3 knockout mice during the late stage of disease significantly improved renal histology and function. Furthermore, transfusion of unfractionated wild-type blood into unconditioned, nonirradiated Col4A3 knockout mice improved the renal phenotype and significantly improved survival. Injection of mouse and human embryonic stem cells into Col4A3 knockout mice produced similar results. Regardless of treatment modality, the improvement in the architecture of the glomerular basement membrane is associated with de novo expression of the alpha3(IV) chain. These data provide further support for testing cell-based therapies for Alport syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.